Candel Therapeutics (CADL) Stock

Candel Therapeutics Inc (ticker CADL) is a clinical-stage biotechnology company focused on developing oncolytic virus immunotherapies for cancer. Its programmes aim to use engineered viruses to selectively kill tumour cells and stimulate anti-tumour immune responses. With a market capitalisation of about $301.37 million, Candel is typical of early-stage biotechs: value is driven by trial results, regulatory milestones and partnership or funding events rather than commercial sales. Investors should expect significant volatility—positive clinical data can materially increase valuation, while trial setbacks, regulatory delays or financing needs can reduce it. Development timelines are long and the company may require additional capital, which can dilute shareholders. This summary is educational and not personalised investment advice. Potential investors should assess their risk tolerance, diversify appropriately and consult a regulated financial adviser before making decisions.